# Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)

> **NCT01983306** · PHASE2 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 292 (actual)

## Conditions studied

- Constipation

## Interventions

- **DRUG:** SP-333 1 mg
- **DRUG:** SP-333 3 mg
- **DRUG:** SP-333 6 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01983306
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-09
- **Final completion:** 2015-04
- **Target enrollment:** 292 (ACTUAL)
- **Last updated:** 2021-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01983306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01983306, "Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01983306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*